| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89254-1mg买3赠1 |
≥98%，钠盐 | ￥700.00 |
10 | - | - | - | - |
|
S89254-5mg买3赠1 |
99.52% | ￥1500.00 |
4 | - | - | - | - |
|
S89254-10mg买3赠1 |
99.52% | ￥2100.00 |
6 | - | - | - | - |
|
S89254-25mg买3赠1 |
99.52% | ￥2800.00 |
2 | - | - | - | - |
|
S89254-100mg |
99.52% | ￥9000.00 |
4 | - | - | - | - |
|
| 产品描述： | Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | GlucagonReceptor | ||||||||||||||||||||
| 体外研究： | Tirzepatide (LY3298176 ) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. | ||||||||||||||||||||
| 体内研究： | Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide | ||||||||||||||||||||
| 参考文献： | 1. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京